Gyre Therapeutics (GYRE) Revenue (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Revenue of $22.5 million for Q1 2026, up 2.09% year-over-year from $22.1 million in Q1 2025, and down 39.46% quarter-over-quarter from $37.2 million in Q4 2025.
Gyre Therapeutics (GYRE) Revenue (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Revenue for 16 consecutive years, with $22.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 2.09% year-over-year to $22.5 million; the TTM figure through Mar 2026 stood at $117.0 million (up 16.3% YoY), while the FY2025 annual figure was $116.6 million, up 10.24% from the prior year.
- Revenue slipped to $22.5 million in Q1 2026 per GYRE's latest filing, from $37.2 million in the prior quarter.
- Across five years, Revenue topped out at $101.5 million in Q4 2022 and bottomed at $794000.0 in Q1 2022.
- Historically, Revenue has averaged $30.7 million across 5 years, with a median of $27.1 million in 2023.
- Annual changes were most pronounced in 2022 — Revenue soared 4125.48% — and 2023, when it slumped 73.25%.
- Gyre Therapeutics' Revenue stood at $101.5 million in 2022, then plunged by 73.25% to $27.1 million in 2023, then advanced by 2.67% to $27.9 million in 2024, then soared by 33.45% to $37.2 million in 2025, then sank by 39.46% to $22.5 million in 2026.
- Business Quant data shows GYRE's Revenue at $22.5 million in Q1 2026, $37.2 million in Q4 2025, and $30.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 29.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.11 Mn |
| Mar 31, 2026 | 22.52 Mn |
| Dec 31, 2025 | 37.20 Mn |
| Sep 30, 2025 | 30.56 Mn |
| Jun 30, 2025 | 26.77 Mn |
| Mar 31, 2025 | 22.06 Mn |
| Dec 31, 2024 | 27.87 Mn |
| Sep 30, 2024 | 25.49 Mn |
| Jun 30, 2024 | 25.23 Mn |
| Mar 31, 2024 | 27.17 Mn |
| Dec 31, 2023 | 27.15 Mn |
| Sep 30, 2023 | 32.04 Mn |
| Jun 30, 2023 | 29.33 Mn |
| Mar 31, 2023 | 24.93 Mn |
| Dec 31, 2022 | 101.50 Mn |
| Mar 31, 2022 | 794,000.00 |
| Dec 31, 2021 | 2.40 Mn |
| Sep 30, 2021 | 2.30 Mn |
| Jun 30, 2021 | 1.13 Mn |
| Mar 31, 2021 | 1.47 Mn |